The potential of miRNAs as biomarkers for multiple myeloma

References

• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Fonseca R, San Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am 2007;21:1115-40. ix
   PubMed Web of Science ®Google Scholar
• Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113:5418-22
   PubMed Web of Science ®Google Scholar
• Weiss BM, Kuehl WM. Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol 2010;3:165-74
   Web of Science ®Google Scholar
• Landgren O, Rajkumar SV. Development of early treatment strategies for high-risk myeloma precursor disease in the future. Semin Hematol 2011;48:66-72
   PubMed Web of Science ®Google Scholar
• Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067-76
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335-48
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Maiso P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013;123:1542-55
   PubMed Web of Science ®Google Scholar
• Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev 2010;24(Suppl 1)):S5-11
   Google Scholar
• Rocci A, Gambella M, Aschero S, et al. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. Br J Haematol 2014;164(6):841-50
   Google Scholar
• Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519-27
   PubMed Web of Science ®Google Scholar
• Noborio-Hatano K, Kikuchi J, Takatoku M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009;28:231-42
   PubMed Web of Science ®Google Scholar
• Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006;42:1574-80
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2013;28(5)):1122-8
   Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149-57
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21
   PubMed Web of Science ®Google Scholar
• Wong KY, Huang X, Chim C. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis. 2012;33(9)):1629-38
   Google Scholar
• Pichiorri F, De Luca L, Aqeilan RI. MicroRNAs: new players in multiple myeloma. Front Genet 2:22-2011
   Google Scholar
• Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330-3
   PubMed Web of Science ®Google Scholar
• Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18:367-81
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
   PubMed Web of Science ®Google Scholar
• Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801
   PubMed Web of Science ®Google Scholar
• Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011;305:59-67
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry KS, Metzeler KH, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013;31:2086-93
   PubMed Web of Science ®Google Scholar
• Marcucci G, Mrózek K, Radmacher MD, et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011;117(4):1121-9
   PubMed Web of Science ®Google Scholar
• Pichiorri F, Palmieri D, De Luca L, et al. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med 2013;210:951-68
   Google Scholar
• Madhavan D, Cuk K, Burwinkel B, et al. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet 2013;4:116
   PubMedGoogle Scholar
• Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 2013;122:1891-9
   PubMed Web of Science ®Google Scholar
• Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108:5003-8
   PubMed Web of Science ®Google Scholar
• Kosaka N, Yoshioka Y, Hagiwara K, et al. Trash or Treasure: extracellular microRNAs and cell-to-cell communication. Front Genet 2013;4:173
   PubMedGoogle Scholar
• Kosaka N, Takeshita F, Yoshioka Y, et al. Exosomal tumor-suppressive microRNAs as novel cancer therapy: “exocure” is another choice for cancer treatment. Adv Drug Deliv Rev 2013;65:376-82
   Google Scholar
• Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10:1470-6
   PubMed Web of Science ®Google Scholar
• Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer 2012;107:1987-96
   PubMed Web of Science ®Google Scholar
• Rocci A, Hofmeister CC, Geyer S, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia 2014. [Epub ahead of print]
   Google Scholar
• Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013;49(16)):3442-9
   Google Scholar
• Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885-90
   PubMed Web of Science ®Google Scholar
• Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009;114:e20-6
   Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23(15):3412-20
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11(1):29-37
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30(24):2946-55
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012;97:442-50
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118:1231-8
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Durie BG, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013;27:711-17
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-84
   PubMed Web of Science ®Google Scholar
• Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269-77
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011;117:553-62
   PubMed Web of Science ®Google Scholar
• Gregory RI, Chendrimada TP, Shiekhattar R. MicroRNA biogenesis: isolation and characterization of the microprocessor complex. Methods Mol Biol 2006;342:33-47
   PubMedGoogle Scholar
• Thomson JM, Newman M, Parker JS, et al. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes & development 2006;20:2202-7
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33
   PubMed Web of Science ®Google Scholar
• O’Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature reviews Cancer 2006;6:857-66
   Google Scholar
• Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61
   PubMed Web of Science ®Google Scholar
• Calin GA, Trapasso F, Shimizu M, et al. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med 2005;352:1667-76
   PubMed Web of Science ®Google Scholar
• Visone R, Veronese A, Rassenti LZ, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 2011;118:3072-9
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14
   PubMed Web of Science ®Google Scholar
• Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell 2010;38:323-32
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597-610
   PubMed Web of Science ®Google Scholar
• Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature 2009;460:529-33
   PubMed Web of Science ®Google Scholar
• Davis BN, Hilyard AC, Lagna G, et al. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008;454:56-61
   PubMed Web of Science ®Google Scholar
• Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50
   PubMed Web of Science ®Google Scholar
• Shen J, Xia W, Khotskaya YB, et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 2013;497:383-7
   PubMed Web of Science ®Google Scholar
• Melo SA, Ropero S, Moutinho C, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 2009;41:365-70
   PubMed Web of Science ®Google Scholar
• Melo SA, Moutinho C, Ropero S, et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010;18:303-15
   PubMed Web of Science ®Google Scholar
• Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 2009;325:965
   PubMed Web of Science ®Google Scholar
• Kim MS, Oh JE, Kim YR, et al. Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers. J Pathol 2010;221:139-46
   PubMed Web of Science ®Google Scholar
• Yang JS, Lai EC. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol Cell 2011;43:892-903
   PubMed Web of Science ®Google Scholar
• Cawley K, Logue SE, Gorman AM, et al. Disruption of microRNA biogenesis confers resistance to ER stress-induced cell death upstream of the mitochondrion. PLoS One 2013;8:e73870
   PubMed Web of Science ®Google Scholar
• Muqbil I, Bao B, Abou-Samra AB, et al. Nuclear export mediated regulation of microRNAs: potential target for drug intervention. Curr Drug Targets 2013;14:1094-100
   Google Scholar
• Melo S, Villanueva A, Moutinho C, et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci USA 2011;108:4394-9
   PubMed Web of Science ®Google Scholar
• Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28:1721-6
   PubMed Web of Science ®Google Scholar
• Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011;29:4781-8
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-18
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-9
   PubMed Web of Science ®Google Scholar
• Zhu W, Qin W, Atasoy U, et al. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009;2:89
   PubMedGoogle Scholar
• Sita-Lumsden A, Dart DA, Waxman J, et al. Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer 2013;108:1925-30
   Google Scholar
• Moussay E, Wang K, Cho JH, et al. MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2011;108:6573-8
   PubMed Web of Science ®Google Scholar
• Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011;3:495-503
   PubMed Web of Science ®Google Scholar
• Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-77
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010;39:133-44
   PubMed Web of Science ®Google Scholar
• He WA, Calore F, Londhe P, et al. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci USA 2014;111(12)):4525-9
   Google Scholar
• Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA 2012;109:E2110-16
   PubMed Web of Science ®Google Scholar
• Ota A, Tagawa H, Karnan S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004;64:3087-95
   PubMed Web of Science ®Google Scholar
• Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-5
   PubMed Web of Science ®Google Scholar
• Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000;97:228-33
   PubMed Web of Science ®Google Scholar
• Schiltz RL, Nakatani Y. The PCAF acetylase complex as a potential tumor suppressor. Biochim Biophys Acta 2000;1470:M37-53
   PubMed Web of Science ®Google Scholar
• Linares LK, Kiernan R, Triboulet R, et al. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 2007;9:331-8
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260-70
   PubMed Web of Science ®Google Scholar
• Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60
   PubMed Web of Science ®Google Scholar
• Junttila MR, Evan GI. p53 – a Jack of all trades but master of none. Nat Rev Cancer 2009;9:821-9
   PubMed Web of Science ®Google Scholar
• Lane D. How cells choose to die. Nature 2001;414:25-27
   PubMed Web of Science ®Google Scholar
• Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009;9:862-73
   PubMed Web of Science ®Google Scholar
• Dickens MP, Fitzgerald R, Fischer PM. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol 2010;20:10-18
   PubMedGoogle Scholar
• Quesnel B, Preudhomme C, Oscier D, et al. Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Br J Haematol 1994;88:415-18
   PubMed Web of Science ®Google Scholar
• Teoh G, Urashima M, Ogata A, et al. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 1997;90:1982-92
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen L, Barlogie B, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 2010;107:7904-9
   PubMed Web of Science ®Google Scholar
• Sarasquete ME, Gutierrez NC, Misiewicz-Krzeminska I, et al. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica 2011;96:468-71
   PubMed Web of Science ®Google Scholar
• Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010;24(3):629-37
   PubMed Web of Science ®Google Scholar
• Corthals SL, Sun SM, Kuiper R, et al. MicroRNA signatures characterize multiple myeloma patients. Leukemia 2011;25(11):1784-9
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669-80
   PubMed Web of Science ®Google Scholar
• Corthals SL, Jongen-Lavrencic M, de Knegt Y, et al. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res 2010;34:677-81
   PubMed Web of Science ®Google Scholar
• Bui TV, Mendell JT. Myc: maestro of MicroRNAs. Genes Cancer 2010;1:568-75
   PubMedGoogle Scholar
• Sun CY, She XM, Qin Y, et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 2013;34:426-35
   PubMed Web of Science ®Google Scholar
• Wu P, Agnelli L, Walker BA, et al. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol 2013;162(3):348-59
   PubMed Web of Science ®Google Scholar
• de Larrea CF, Navarro A, Tejero R, et al. Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation. Clin Cancer Res 2012;18(13):3697-704
   PubMed Web of Science ®Google Scholar
• Rio-Machin A, Ferreira BI, Henry T, et al. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia 2013;27:925-31
   PubMed Web of Science ®Google Scholar
• Lionetti M, Musto P, Di Martino MT, et al. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res 2013;19:3130-42
   PubMed Web of Science ®Google Scholar
• Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014;99:511-18
   Google Scholar
• Rocci A, Hofmeister C, Omede P, et al. Circulating microRNA in multiple myeloma: differences with healthy subjects and correlations with clinical parameters. European Hematology Association Meeting 2012. abstract #553
   Google Scholar
• Harshman SW, Canella A, Ciarlariello PD, et al. Characterization of Multiple Myeloma Vesicles by Label-Free Relative Quantitation. Proteomics 2013;13(20):3013-29
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Baladandayuthapani V, Lin HY, et al. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: therapeutic Implications. Leukemia 2014;28(2):373-83
   PubMed Web of Science ®Google Scholar
• Gebhard AW, Jain P, Nair RR, et al. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma. Mol Cancer Ther 2013;12(11):2446-58
   Google Scholar